Sernova Biotherapeutics Inc · HAN:PSH0

Sernova Biotherapeutics Inc financial statements

Sernova Biotherapeutics Inc's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in CAD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue342.6K540.3K445.6K440.0K267.2K225.2K61.5K64.5K39.9K7.56K
Gross profit-342.6K-540.3K-445.6K-440.0K-267.2K-225.2K-61.5K-64.5K-39.9K-7.56K
Research and development7.28M22.4M32.3M16.9M4.64M2.76M2.01M2.23M1.54M1.20M
Selling, general and administrative7.50M8.97M8.46M7.83M2.29M2.48M2.00M1.47M1.10M1.30M
Operating income-15.1M-31.8M-41.1M-24.2M-6.87M-5.22M-3.97M-3.69M-2.63M-2.49M
Depreciation and amortization342.6K540.3K445.6K440.0K267.2K225.2K61.5K64.5K39.9K7.56K
EBITDA-14.8M-31.3M-40.7M-23.7M-6.60M-5.00M-3.91M-3.62M-2.59M-2.48M
Interest expense754.8K586.9K32.1K118.0K58.4K86.3K7.27K9.71K13.8K9.69K
Income before tax-15.8M-32.2M-39.6M-24.4M-6.97M-5.32M-3.97M-3.70M-2.64M-2.50M
Income tax-92.2K7.00K-629.0K118.0K58.4K86.3K7.27K9.71K13.8K9.69K
Net income-15.7M-32.2M-39.0M-24.5M-7.02M-5.41M-3.98M-3.70M-2.64M-2.50M
Earnings per share, basic-0.05-0.10-0.13-0.09-0.03-0.03-0.02-0.02-0.02-0.02

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents265.0K6.01M8.72M3.78M27.9M3.95M1.80M1.74M2.63M5.20M
Short-term investments011.1M46.0M002.01M1.00M1.00M700.0K
Receivables122.6K298.1K1.05M1.15M448.9K506.8K735.0K471.6K641.4K231.4K
Current assets522.6K6.47M21.0M51.1M28.3M4.61M5.32M3.32M4.31M6.20M
Property, plant and equipment17.7K833.9K507.4K653.7K564.7K203.4K251.5K289.0K238.5K26.6K
Goodwill316.4K
Total assets764.2K7.53M22.1M52.5M29.8M5.73M5.57M3.61M4.55M6.23M
Accounts payable17.7M17.2M6.85M3.61M379.5K529.4K472.9K182.6K182.9K116.0K
Current liabilities24.8M20.0M9.59M4.74M1.48M878.1K686.8K341.2K901.1K846.3K
Long-term debt1.04M0702.6K
Total debt4.77M569.9K136.1K276.0K393.4K734.4K
Total liabilities25.8M20.5M9.59M4.88M1.75M1.58M686.8K341.2K901.1K846.3K
Shareholders' equity-25.1M-13.0M12.5M47.6M28.1M4.14M4.88M3.26M3.65M5.38M
Shares outstanding328.3M307.0M303.3M273.6M245.5M197.3M175.9M159.5M158.2M148.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-10.9M-18.9M-30.3M-14.4M-6.84M-3.94M-4.19M-3.92M-2.74M-2.55M
Capital spending-3-3-99.3K-329.0K-17.2K-1.01M-24.0K-115.0K-251.7K-19.4K
Free cash flow-10.9M-18.9M-30.4M-14.8M-6.86M-4.94M-4.22M-4.03M-2.99M-2.57M
Cash from investing25.0K11.1M34.8M-46.3M-228.8K994.4K-1.02M-110.7K-551.7K1.93M
Cash from financing5.14M5.07M503.5K36.7M31.0M5.10M5.27M3.14M720.1K5.61M
Share buybacks248.6K4.98M036.5M29.9M3.56M4.73M2.81M470.5K255.1K
Change in cash-5.75M-2.71M4.95M-24.1M23.9M2.15M57.8K-888.2K-2.57M4.99M